幽门螺杆菌尿素酶单克隆抗体的研制及鉴定

应用杂交瘤技术 ,建立稳定分泌抗幽门螺杆菌尿素酶单克隆抗体 (HPU McAb)的细胞系。用纯化幽门螺杆菌尿素酶 (HPU)抗原加福氏佐剂免疫BALB/c小鼠 ,按常规方法进行细胞融合 ,以纯化HPU抗原包被 ,间接ELISA方法筛选 ,并经多次有限稀释法克隆。获得 6株抗HPU的杂交瘤 ,腹水效价达 1∶6 .4× 10 4～ 1∶2 .5 6× 10 5,特异性专一 ,并对其进行体内外连续传代 3个月 ,分泌抗体能力稳定。IgG亚类分型主要为IgG1型。该细胞系能稳定分泌幽门螺杆菌尿素酶单抗。     

兔抗人和大鼠烧伤皮肤毒素提取物的免疫血清制备及抗原性分析

为进一步确证和研究人和大鼠烧伤毒素提取物的抗原性及其特征,以及同以新鲜皮制成的提取物在免疫学特性方面的异同,将人和大鼠烧伤皮肤与新鲜皮肤的提取物,经各种生物化学分析及定量后,分成四组,每组(?)只兔子,分别以福氏完全佐剂抗原、不完全佐剂和水剂抗原免疫,制成(?)种免疫血清。对上述抗血清先后经过免疫双相扩散、单相扩散、免疫电泳、火箭免疫电泳等方法的分析,结果表明,兔抗人和大鼠烧伤皮肤毒素提取物的抗原性较强,(?)双扩和免疫电泳上均出现一很强的抗原成分,抗体效价可达1∶16～1∶32(双扩);而人和大鼠新鲜皮肤提取物的抗原性很     

蝙蝠血清IgG的纯化及兔抗蝙蝠IgG酶标抗体的制备

目的纯化蝙蝠血清IgG,制备兔抗蝙蝠IgG酶标抗体。方法采用亲和层析纯化法纯化蝙蝠血清IgG,SDS-PAGE电泳鉴定蝙蝠IgG纯度。免疫大白兔制备兔抗蝙蝠IgG抗血清,免疫双扩散法测定抗血清效价,亲和层析纯化法纯化抗血清IgG。用改良过碘酸钠标记法制备兔抗蝙蝠IgG酶标抗体,直接ELISA和Western blot法对兔抗蝙蝠IgG酶标抗体进行工作浓度测定。结果纯化的蝙蝠血清IgG,其SDS-PAGE测定纯度大于95%;免疫大白兔所制备的抗血清免疫双扩散效价为1∶64;用改良过碘酸钠标记法制备兔抗蝙蝠IgG酶标抗体,其直接ELISA和Western blot工作浓度分别为1∶12800和大于1∶2000。结论制备了蝙蝠血清IgG的抗血清和酶标抗体,为蝙蝠的血清学检测体系提供了技术和资源储备。     

抗Ⅱ型登革病毒蛋白抗体的制备和特点分析

本研究旨在制备和鉴定小鼠抗Ⅱ型登革病毒（DENV‐2）10种蛋白的抗体,为后续相关研究提供实验材料。利用真核表达载体pReceiver构建DENV‐210种蛋白的重组质粒,提取质粒 DNA ,肌内注射免疫小鼠,共免疫4次。末次免疫后2周取小鼠血清,利用DENV‐2感染的Vero细胞和DENV‐2各蛋白的稳定表达细胞,通过酶联免疫吸附试验（ELISA）、间接免疫荧光法（IFA）和蛋白免疫印迹法评价免疫效果,分析抗体的特点。DNA免疫小鼠后获得抗DENV‐210种蛋白的抗血清,抗体效价波动于1∶400～1∶16127之间,以抗E蛋白抗体效价最高,达1∶16127,而抗NS3、NS4b、NS5蛋白抗体效价较低,仅为1∶400。利用DENV‐2感染的Vero细胞和稳定表达病毒蛋白的EAhy926细胞进行IFA染色,抗DENV‐2各蛋白的抗血清均可特异性识别DENV‐2抗原。蛋白免疫印迹结果显示,抗E、NS1、NS4b和NS5蛋白抗体能识别热变性蛋白,其他抗血清未呈现阳性反应条带。本研究提示,DNA免疫小鼠所获得的抗DENV‐2各蛋白抗体能特异性识别自然感染或模拟自然感染状态下的DENV‐2蛋白,可为后续相关研究提供工具,也表明DNA免疫法可作为抗体制备的一种策略。     

模拟胃酸条件下的幽门螺杆菌CAT特异性抗体活性研究

幽门螺杆菌是常见的感染性病原菌,人类多种疾病发生与此菌感染有关。预防和治疗菌体感染及引发的相关疾病仍是现代医学面临的课题。实验利用原核表达的幽门螺杆菌过氧化氢酶(1~380 aa)免疫家兔,获得效价为1∶6 000的特异性抗血清,经硫酸铵沉淀法得到初步纯化的抗体。在体外模拟胃酸环境下(pH3.4)将抗体进行水解。SDS-PAGE结果显示,抗体的重链能被水解。水解后的抗体产物经ELISA方法检测,仍然具有与抗原特异性结合的能力。实验结论证实,在体外环境下特异性幽门螺杆菌抗体保护作用不会被胃蛋白酶的水解而破坏,提示口服特异性抗体预防和治疗幽门螺杆菌感染可能是一条可行的途径。     

利用展示尿素酶B表位的大肠杆菌菌蜕递送幽门螺杆菌核酸疫苗

探讨和分析了重组大肠杆菌菌蜕递送系统能否进一步提高幽门螺杆菌核酸疫苗的免疫应答水平.首先构建了展示尿素酶B表位的重组大肠杆菌菌蜕,然后以此菌蜕包裹幽门螺杆菌核酸疫苗pcDNAKAT,经DNA凝胶电泳、荧光显微镜观察和FACS分析,表明该质粒DNA可以非特异地结合到大肠杆菌菌蜕内膜上.该核酸疫苗经重组菌蜕包裹后免疫小鼠,其血清抗过氧化氢酶抗体效价由单独免疫时的1∶(307±39)提高到1∶(520±54),二者差异极显著(P=0.005 8),结果表明利用菌蜕递送系统能较好地提高核酸疫苗的免疫应答水平.     

小鼠组蛋白去乙酰化酶2多肽抗血清的制备

目的利用人工合成小鼠组蛋白去乙酰化酶2（histone deacetylase 2,HDAC2）多肽制备特异性抗HDAC2抗血清,用于相关疾病的体内外诊断。方法根据HDAC2基因编码的氨基酸序列合成多肽,与载体偶联后免疫动物,所制备的抗血清用ELISA、Western blot及免疫组织化学方法鉴定。结果 ELISA检测表明所制备的抗血清可同多肽抗原发生阳性反应,效价1∶4 000;Western blot结果显示抗血清可与多肽抗原及APP/PS1转基因小鼠的脑组织发生反应;免疫血清1∶100,1∶200,1∶400,1∶800四个稀释度均能与小鼠脑组织中的HDAC2反应。结论所制备的多肽抗血清可识别组织及血清中的HDAC2,可应用于相关领域的体内外研究。     

氢氧化铝佐剂制备工艺的建立及其在鼠疫疫苗中的免疫效果评价

目的建立氢氧化铝佐剂制备工艺,并吸附抗原配制鼠疫疫苗,对其进行免疫效果评价。方法采用氯化铝与氢氧化钠反应生成氢氧化铝胶体,通过优化制备工艺,制备出纳米级铝佐剂,并对其进行连续4批质量检测,将其与丹麦ALH铝佐剂在吸附率、沉降率、粒径、配制鼠疫疫苗安全性及免疫原性方面进行比较。结果 4批次氢氧化铝含量平均值为18.67 mg/mL,氯化钠含量平均值为29.60 mg/mL,平均pH为5.66;各批次氢氧化铝佐剂沉降率及吸附率检测结果均符合《中华人民共和国药典》2020版(四部)的检测要求;粒径控制已达到纳米级,平均值为100～600 nm;配制鼠疫疫苗安全性检测结果合格,20200404批铝佐剂与ALH铝佐剂分别配制鼠疫疫苗免疫NIH小鼠,20200404疫苗组V抗体IgG、IgG1抗体效价均高于ALH疫苗组,差异均有统计学意义(P0.000 5);20200404疫苗组V抗体IgG2a抗体效价与ALH疫苗组差异无统计学意义(P0.05);20200404疫苗组与ALH疫苗组F1抗体IgG、IgG1、IgG2a抗体效价差异均无统计学意义(P0.05)。结论成功建立了氢氧化铝佐剂制备工艺,为制备鼠疫疫苗用铝佐剂奠定了基础。     

鹦鹉热衣原体重组主要外膜蛋白诱导小鼠免疫应答的观察

用鹦鹉热衣原体 (Chlamydiapsittaci,Cps)重组主要外膜蛋白 (RecombinantMajorOuter Membraneprotein ,r MOMP)免疫小鼠 ,观察小鼠免疫后对r MOMP和Cps菌体蛋白的免疫应答。r MOMP皮下注射免疫BALB/c小鼠 ,对照组仅注射佐剂。免疫前和第 3次免疫后 10d收集血清 ,以常规ELISA法检测抗体效价 ;MTT方法检测脾淋巴细胞对r MOMP和Cps菌体蛋白的特异性增殖反应。免疫组小鼠在免疫 38d后免疫血清中抗r MOMP的抗体效价可达 1∶2× 10 4,抗Cps菌体蛋白的抗体效价为 1∶4× 10 3 ;脾淋巴细胞对r MOMP和Cps菌体蛋白的增殖指数明显高于佐剂对照组 (p <0 .0 1,具有显著性意义。r MOMP在小鼠体内可诱导Cps特异性的体液免疫和细胞免疫应答 ,说明具有较好的免疫原性     

荒漠昆虫小胸鳖甲几丁质酶抗血清的制备及抗体效价检测

目的几丁质酶是昆虫重要的防御物质,本研究采用DNA-蛋白质联合免疫策略制备荒漠昆虫小胸鳖甲几丁质酶(MpCHI786)的抗血清,用于检测小胸鳖甲在外界不良条件下几丁质酶的变化。方法从小胸鳖甲成虫中提取总RNA,反转录后RT-PCR扩增Mpchi786 cDNA,构建原核表达载体pET30a-Mpchi786,在大肠杆菌BL21中用IPTG诱导表达获得融合蛋白His-MpCHI786。对融合蛋白切胶纯化后与弗氏佐剂混合作为抗原。另外,构建真核表达质粒pcDNA3.0-Mpchi786,对小鼠尾静脉高压注射,8 h后RT-PCR检测其在肝脏的瞬时表达。以pcDNA3.0-Mpchi786肌肉注射免疫小鼠3次后,再用His-MpCHI786融合蛋白加强免疫2次,DNA免疫和免疫结束后收集免疫小鼠的血清,ELISA和Western blot法检测抗血清效价和特异性。结果 RT-PCR结果显示尾静脉高压注射8 h后,pcDNA3.0-Mpchi786质粒在小鼠肝脏有特异性表达。Western blot检测表明,用His-MpCHI786融合蛋白作为抗原,pcDNA3.0-Mpchi786DNA质粒免疫3次的抗血清和His-MpCHI786融合蛋白加强免疫2次后的抗血清都显示了特异性反应条带。ELISA检测结果显示抗血清效价高达1∶204 800以上。结论利用DNA-蛋白质联合免疫法能够获得效价高、特异性的小胸鳖甲几丁质酶MpCHI786的抗血清。     

幽门螺旋杆菌重组尿素酶B亚基的纯化及其免疫学性质的研究

目的:幽门螺旋杆菌(Hp)尿素酶是Hp重要的定制因子和致病因子,Hp尿素酶活性位点位于Hp尿素酶B亚基(UreB),研发基于UreB的Hp疫苗是一种很有前景的防治Hp感染的策略。方法:主要利用基因克隆技术从幽门螺旋杆菌标准菌株SS1(Hp SS1)获得Hp尿素酶B亚基基因,并构建含有重组Hp尿素酶B亚基(rUreB)基因的重组表达载体pET-rUreB及其重组菌株;重组菌株经蛋白表达和优化后,利用Ni-NTP镍离子亲和层析和DEAE Sepharose FF阴离子交换层析纯化重组尿素酶B亚基(rUreB),并进一步通过腹腔注射免疫BALB/c小鼠,研究rUreB的免疫学性质。结果:通过基因克隆技术成功获得了Hp尿素酶B亚基基因,并成功构建了重组表达载体pET-rUreB及其重组菌株BL21(DE3)/pET-rUreB,经蛋白表达优化及纯化,可获得高纯度(96.5%)的重组蛋白rUreB。重组蛋白rUreB辅以弗氏佐剂腹腔注射免疫BALB/c小鼠,经间接ELISA鉴定小鼠能够产生针对天然Hp尿素酶和UreB的高滴度特异性抗体,且能够显著性抑制Hp尿素酶的活性。结论:重组Hp尿素酶B亚基能够在大肠杆菌表达系统中获得较高水平的表达,具有较高的免疫学特异性,其抗体能够有效抑制Hp尿素酶活性。为研究基于尿素酶的防治Hp感染的Hp疫苗奠定了一定的实验基础。     

Evaluation of therapeutic efficacy of adjuvant Helicobacter pylori whole cell sonicate in mice with chronic H. pylori infection

Successful prophylactic administration of Helicobacter pylori whole cell sonicate (WCS) plus complete Freund's adjuvant (CFA) or aluminum hydroxide (ALM) against subsequent H. pylori infection was reported recently. Here we tested the effect of WCS plus TiterMax Gold (TMX) or ALM in mice with chronic H. pylori infection. Mice with chronic (18 weeks) H. pylori infection were injected intraperitoneally with H. pylori (Sydney strain) WCS plus ALM or TMX once weekly for three times. The number of colonizing H. pylori in the stomach, IgG1 and IgG2a levels, and local inflammatory status were determined after therapeutic immunization. H. pylori specific IgG1, but not IgG2a, was significantly induced in mice immunized with H. pylori WCS plus TMX or ALM. Immunization did not result in reduction of bacterial count or recruiting inflammatory cells to the stomach. Adjuvant H. pylori WCS resulted in induction of CD4+ Th2 cell-mediated immunity although it did not reduce bacterial density in mice with chronic H. pylori infection. Our results implied that CD4+ Th1 cell-mediated immunity, rather than Th2 cell dominant immunity, might play a role in reducing the number of bacteria in chronic H. pylori infection.     

Adjuvant synergy: the effects of nasal coadministration of adjuvants

Modern peptide and protein subunit vaccines suffer from poor immunogenicity and require the use of adjuvants. However, none of the currently licensed adjuvants can elicit cell-mediated immunity or are suitable for mucosal immunization. In this study we explored the immunological effect of nasal co-administration of adjuvants with distinct functions: cholera toxin subunit B, a potent mucosal adjuvant that induces strong humoral responses, muramy di-peptide (MDP), an adjuvant known to elicit cell mediated immunity but rarely used nasally, and chitosan, an adjuvant that achieves specific physiological effects on mucosal membranes that improve antigen uptake. Groups of five female BALB/c mice received on days 1 and 56 nasal instillations of the recombinant Helicobacter pylori antigen urease admixed to single or multiple adjuvant combinations. Serum IgG kinetics were followed over 24 weeks. At the conclusion of the experiment, local antibody responses were determined and antigen-specific recall responses in splenocyte cultures were assayed for proliferation and cytokine production. The combination of adjuvants was shown to further contribute to the increased antigenicity of recombinant H. pylori urease. The data presented here outline and support facilitation of increased immunomodulation by an adjuvant previously defined as an effective mucosal adjuvant (chitosan) for another adjuvant (MDP) that is not normally effective via this route.     

Therapeutic immunization against Helicobacter pylori infection in the absence of antibodies

Helicobacter pylori is an important human pathogen. Prophylactic immunization with bacterial antigen plus an adjuvant protects mice against challenge with live H. pylori. Surprisingly, it was found that immunizations of mice already infected with Helicobacter also influenced bacterial colonization. This concept of therapeutic immunization is a novel phenomenon. Because H. pylori lives in the lumen of the stomach, it was initially hypothesized that the protective mechanism would involve induction of secretory IgA. However, work with knockout mice has demonstrated that prophylactic immunization is equally effective in mice deficient in IgA and even in microMT mice lacking B lymphocytes. Currently nothing is known about therapeutic vaccination and the effect of immunizing a host with an ongoing ineffective immune response. To address this, we infected B-cell deficient, microMT mice with H. pylori and therapeutically immunized them four times in 3 weeks with bacterial sonicate and cholera toxin adjuvant. These immunizations significantly reduced colonization by H. pylori. The antibody- negative status of the microMT mice was confirmed by ELISA. Thus, therapeutic immunization stimulates an immune response, which reduces H. pylori infection via a mechanism that is antibody independent. How this is achieved remains to be determined, but may well involve a novel immune mechanism.     

Preparation and Effect of Different Adjuvants on the Immunogenic Activity of Mycobacterial Ribosomal Fraction

Several emulsified and two nonemulsified incomplete adjuvants were examined for their adjuvant activity by use of mycobacterial ribosomal fractions as a substrate. A good adjuvant is defined as one which produces a high immunological response with the ribosomal fraction in mice to infection with virulent tubercle bacilli. Freund's incomplete adjuvant, consisting of Aquaphor and heavy mineral oil, and Arlacel A plus hexadecane were the best adjuvants tested. Aquaphor plus light mineral oil and Arlacel A plus 7-n-hexyloctadecane were not quite as effective. Peanut oil was not satisfactory when emulsified with either Aquaphor or Arlacel A. A moderate degree of immunity was produced in mice vaccinated with ribosomal fraction mixed with aluminum hydroxide gel. Sodium alginate mixed with ribosomal fraction produced a low degree of immunity only with the highest vaccinating dose. It was found that the effectiveness of the emulsified type of adjuvant depended upon the method of preparation. Careful standardization of technique to produce uniform and complete emulsification was essential for maximal adjuvant activity using minimal vaccinating doses. A rapid and practical method of preparing emulsified adjuvants is given. The mode of action of incomplete adjuvants as employed in these experiments is discussed, and it is thought that they acted primarily by protecting the ribosomes from being inactivated by host ribonuclease before they were engulfed by the macrophages.     

Evaluation of the bacterial endotoxin test for quantification of endotoxin contamination of porcine vaccines.

We investigated the application of the bacterial endotoxin test for the quantification of the endotoxin contamination of various commercial porcine vaccines. In endotoxin-spiked samples, Freund's complete adjuvant and aluminum hydroxide gel adjuvant failed to interfere with the results of the endotoxin test, and both recovery ratios were within the permissible range mentioned in the Japanese Pharmacopoeia. At the various dilutions tested, none of the adjuvants in commercial porcine vaccines caused noteworthy interference in the test. In addition, none of the 39 samples of porcine vaccines approved in Japan induced an interfering effect in the endotoxin test. Our findings suggest that the bacterial endotoxin test using endotoxin-specific Limulus amoebocyte lysate (LAL) can detect endotoxin contamination in commercial porcine vaccines containing either oil or aluminum adjuvants.     

An evaluation of several adjuvant emulsion regimens for the production of polyclonal antisera in rabbits.

Emulsion adjuvants have been used for production of polyclonal antisera in rabbits (Oryctolagus cunniculi) for decades. Complete Freund's adjuvant has a reputation as a very effective immunoenhancer, but adverse physiological effects, including fever, inflammation and sterile abscess formation, have prompted a search for alternatives to complete Freund's. In this study, we quantitatively compared five adjuvant regimens: (a) a primary inoculation with complete Freund's followed by three boosts with incomplete Freund's; (b) four serial inoculations of incomplete Freund's adjuvant augmented with 6-bromoguanisine; (c) four serial inoculations with RIBI's MPL + TDM + CWS adjuvant emulsion; (d) four serial inoculations with Montanide ISA 50 emulsion; and (e) four serial inoculations with Montanide ISA 70 emulsion. We chose a small (12 amino acid) chain polypeptide coupled to bovine serum albumin as our test antigen. When compared, no system could be seen to be significantly better than a regimen of a primary immunization with complete Freund's adjuvant followed by serial reimmunization with incomplete Freund's adjuvant. The commercially available RIBI adjuvant produced significantly lower antibody levels, while other systems produced essentially equivalent levels. With all five adjuvants, antibody quantities plateaued after the second injection and further immunization did not increase titers significantly. Boost injections did yield greater intradermal tissue reaction than primary inoculations, and intramuscular inoculum volumes of 0.4 cc caused chronic lesions still detectable by the gross necropsy 2 weeks after the final injection.     

Immunological adjuvants efficiently induce antigen-specific T cell responses in old mice: implications for vaccine adjuvant development in aged individuals

The morbidity and mortality of infectious diseases are significantly increased in aged humans. Hence, vaccination has been suggested as a means to reduce or prevent the impact of infections on old individuals. However, it has remained unresolved whether or not standard vaccine adjuvants such as aluminum hydroxide (Alum) are similarly efficacious in old individuals, as compared to young adults. Here, we have investigated the effects of prototypic immunological adjuvants, complete Freund's adjuvant (CFA), incomplete Freund's adjuvant (IFA), or Alum on HEL-specific T cell responses in young adult and old mice. We report that independent of the adjuvant used, the induced T cell responses to the prototypic protein antigen hen eggwhite lysozyme (HEL) were similar in young adult and old mice in terms of cytokine production, T cell frequencies, determinant specificity, and T cell repertoire. The results suggest that vaccine adjuvants developed in young adults should be equally effective in inducing T cell immunity in old individuals.     

Immunogenic Properties of Colloidal Gold

We studied the capacity of colloidal gold for enhancing specific and nonspecific immune response in laboratory animals (rabbits, rats, and mice) immunized with antigens of various nature. The antibody titers obtained with colloidal gold as a carrier were higher as compared to the standard immunization techniques (free antigen or its combination with Freund's adjuvant). Application of colloidal gold also enhanced nonspecific immune responses, such as lysozyme concentration in the blood, activity of the complement system proteins, as well as phagocytic and bactericidal activities. The antibodies were tested by immunodot assay using gold markers. Immunization of the animals with colloidal gold conjugates with haptens or complete antigens (without other adjuvants) was shown to induce the production of highly active antibodies. In addition, the amount of antigen used for animal immunization with colloidal gold was an order of magnitude lower, compared to immunization with complete Freund's adjuvant. This fact can be evidence for adjuvant properties of colloidal gold proper.     

幽门螺杆菌表面抗原免疫保护作用的体外与活体研究

目的：调查幽门螺杆菌（Hp)几种表面蛋白体外对T细胞增殖的影响和在小鼠体内的免疫保护作用。方法：评价Hp全菌抗原、尿原酶（Urease)、黏附素（hpaA)、外膜蛋白25（Hop25)和38（Hop38)对人外周血T细胞及小鼠CD4^ T细胞增殖的影响;与佐剂合用,评价上述重组蛋白对小鼠Hp感染的免疫预防作用。结果：Urease和Hop25可刺激人及鼠T细胞增殖,hapA只能刺激Hp^ PBL增殖,而Hop38则有毒性作用;Hop25和Hop38均可产生60％的完全保护,hpaA可产生100％的部分保护即降低细菌定植密度,而Urease只能产生40％的部分保护。结论：外膜蛋白可能是一组高效的Hp疫苗免疫原;其长期免疫效果及对T细胞功能的活体调节作用尚需进一步评价。国际上尚未见相关报道。